Mizuho downgrades Chemours as analysts reset targets lower

The short position has eased slightly on the week but remains elevated. Short interest dipped about 2% over seven days to 10.2% of the free float, roughly 15.3 million shares, after the sharper build in late September flagged in last week's note. The monthly gain of 16% confirms the bearish directional trend is intact even if weekly momentum has softened. The FINRA fortnightly settlement put days-to-cover at 8.2, giving the position meaningful weight relative to daily volume. The lending market remains entirely untroubled. Availability is running at roughly 1,721% relative to short interest, the most relaxed it has been in several weeks, meaning there is no squeeze pressure and no friction for new shorts entering the trade. Cost to borrow at 0.46% is trivially low. The ORTEX short score at 54.6 is essentially flat on the week, consistent with a position that is large but not accelerating.

Options are not adding much signal right now. The put/call ratio at 0.51 is almost exactly in line with its 20-day average of 0.50, with a z-score barely above zero. That is a meaningful contrast to late September, when the PCR ran above 0.57 and options traders were more visibly hedged. The current read is closer to neutral than defensive, which sits somewhat awkwardly alongside a stock down 6% on the week and analysts cutting numbers.

The insider cluster from early August remains the most constructive data point in the snapshot, though it is now two months stale. The CEO, CFO, and several directors bought open-market shares in the $14.94 to $15.83 range in the days after the August print, which sent the stock down roughly 15% in a single session. Net insider buying over the past 90 days totals around $489,000 across more than 31,000 shares, all discretionary purchases rather than plan-driven trades. The stock has since slipped back below those August purchase prices, sitting at $13.20 today. That gap between where insiders bought and where the stock trades is the central tension going into November 5.

The earnings history underscores the risk around that date. The August print produced a one-day fall of roughly 15.7%, followed by a further 15% decline over the next five sessions. The prior event was essentially flat on the day. Two data points is a thin sample, but the distribution is skewed hard to the downside, and the bear case on HFC demand and TiO2 pricing pressure has not materially changed since August. What to watch between now and November 5 is whether the Mizuho downgrade triggers further target reductions from the remaining buy-rated names, and whether short interest resumes building or the weekly softening marks a genuine pause.